Eikon Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	104.87	129.18	112.78
Short-Term Investments	270.99	90.93	317.63
Cash & Short-Term Investments	375.85	220.11	430.41
Cash Growth	-	-48.86%	-
Prepaid Expenses	14.24	7.38	6.01
Restricted Cash	0.4	0.4	-
Total Current Assets	390.5	227.89	436.43
Property, Plant & Equipment	241.15	259.13	86.88
Other Long-Term Assets	8.39	4.22	2.4
Total Assets	642.34	491.24	525.71
Accounts Payable	4.28	17.58	2.19
Accrued Expenses	30.05	29.16	21
Current Portion of Leases	9.91	9.31	5.05
Other Current Liabilities	0.16	0.4	3.21
Total Current Liabilities	44.39	56.45	31.44
Long-Term Leases	230.83	193.15	26.69
Other Long-Term Liabilities	10	5.35	0.73
Total Liabilities	285.22	254.95	58.86
Common Stock	-	0	0
Additional Paid-In Capital	36.5	33.01	19.75
Retained Earnings	-840.85	-604.94	-361.13
Total Common Equity	-804.35	-571.93	-341.37
Shareholders' Equity	357.12	236.29	466.85
Total Liabilities & Equity	642.34	491.24	525.71
Total Debt	240.73	202.46	31.74
Net Cash (Debt)	135.12	17.65	398.68
Net Cash Growth	-	-95.57%	-
Net Cash Per Share	48.16	7.01	196.75
Filing Date Shares Outstanding	2.95	2.87	2.03
Total Common Shares Outstanding	2.95	2.87	2.03
Working Capital	346.1	171.44	404.99
Book Value Per Share	-272.57	-199.28	-168.47
Tangible Book Value	-804.35	-571.93	-341.37
Tangible Book Value Per Share	-272.57	-199.28	-168.47
Machinery	58.98	54.36	49.47
Construction In Progress	0.13	96.86	5.42
Leasehold Improvements	121.81	18.61	18.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q